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Context 
Radiotherapy for breast cancer is in an exciting era. Technological improvements in radiotherapy 
delivery and imaging are being used to achieve dose inhomogeneity [1] complex planning within 
trials [2], and for cases requiring extensive nodal irradiation [3]. These complex treatments require 
the use of advanced verification imaging i.e. image guided radiotherapy (IGRT). IGRT is defined in 
many ways, and includes imaging throughout the radiotherapy process. In this Editorial IGRT is used  
specifically to refer to imaging at the time of treatment at levels 2c to 2e, under the National 
Radiotherapy Implementation Group Report on IGRT [4]. This is the highest level of inter-fraction 
intervention in the scheme and requires matching and analysis using target anatomy or implanted 
markers as surrogates. 
The necessity of IGRT in complex radiotherapy raises the issue of how its impact can be tested. 
Randomised trials are appropriate to test many research hypotheses but not all. For example it is not 
ethical to set up a no imaging versus imaging study where it is clear that a new imaging technology is 
both superior, and required, to deliver high quality radiotherapy. We present an exemplar of how 
this issue may be resolved by using the IMPORT HIGH trial as a case study. 
 
Intensity Modulation and Partial Organ Radiotherapy (IMPORT) HIGH  
IMPORT HIGH (CRUK/06/003) is a Phase III randomised trial of radiotherapy dose escalation in 
women at higher than average risk of local cancer recurrence after breast conserving surgery [5,6].  
It is funded by Cancer Research UK and coordinated by the Institute of Cancer Research Clinical Trials 
and Statistics Unit. Radiotherapy treatment within the IMPORT HIGH trial requires a conformal 
photon boost in the control arm and a simultaneous integrated boost in the test arms. There was a 
steep increase in the complexity of planning, treatment and imaging within the trial compared with 
standard UK practice. The trial changed practice in the UK by requiring surgical clips to be inserted 
into the tumour bed at the time of surgery [7,8].  This was crucial so that the tumour bed and partial 
breast volumes could be defined correctly, and to verify the tumour bed position at the time of 
treatment. A planning study demonstrated the complex dose distributions could be achieved and 
delivered with a range of planning systems and treatment units hence widespread implementation 
was feasible[9]. The tight  (5mm) margins on the tumour bed volume and the need to maintain dose 
discrimination in the simultaneous boost plan means that it was not appropriate to use standard 
imaging based on bony anatomy for verification.  
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All participating centres use IGRT with a defined verification protocol. Although this ensures safe 
treatment and adherence to the trial protocol it does not enable an assessment of the efficacy of 
IGRT compared to standard imaging as no patients are imaged with standard portal imaging. This 
raises important questions about image guidance:  how can the efficacy of IGRT be tested whilst still 
providing the highest quality treatments for the patients? and what is the variation, if any,  with the 
type of imaging equipment used? 
IMPORT – IGRT Study 
IMPORT HIGH provides a unique opportunity to answer these questions and the IMPORT-IGRT study 
was created as a sub-study within it to investigate the efficacy of IGRT in breast radiotherapy. The 
projeĐt ǁas titled ͚EǀaluatioŶ of Iŵage Guided ‘adiotherapy for ŵore aĐĐurate Partial Breast 
Intensity-Modulated Radiotherapy: comparison with standard imaging technique͛ and was funded 
by the Medical Research Council under the Efficacy and Mechanism Evaluation programme 
(reference 09/150/16). It was administered by the National Institute for Health Research and ran 
from 03.2010 to 08.2013.  
 
IMPORT-IGRT had a multi-institutional observational design. Data were collected from 218 patients 
treated within IMPORT HIGH from 5 radiotherapy centres giving a total of 1574 imaging data sets. 
The centres used a variety of standardly-available imaging equipment allowing 2D kV, and 3D kV and 
MV iŵagiŶg iŶforŵatioŶ to ďe ĐolleĐted aŶd Đoŵpared. There ǁas Ŷo ĐhaŶge to patieŶts͛ treatŵeŶts 
or verification from that defined by the IMPORT HIGH protocol: standard imaging data were 
obtained from the IGRT information. This design allows IGRT to be assessed in an ethical way as all 
patients receive the best treatment and imaging. 
 
Data were collected on the daily set up accuracy and reproducibility of: (i) image guidance, (ii) 
standard portal imaging (deduced from the IGRT data by matching to bony anatomy rather than the 
surgical clips) and (iii) laser external set-up (using no shift from the treatment images). The primary 
outcome of the study was evaluating the population systematic error data for IGRT, standard 
imaging and using external anatomy for set-up (no imaging shift).  From these, and the measured 
population random error data, estimates of tumour bed planning target margin sizes were 
calculated. These margin data were used to create a series of treatment plans for 60 patients. These 
data informed on PTV coverage and non-target tissue doses, particularly the volume of breast tissue 
spared high dose. Analysis of data from a range of clinical trials was used to comment on the risk of 
late adverse effects from volume changes with the use of IGRT compared to standard or no imaging. 
Data on the time taken to acquire and analyse images were collected from the participating centres.   
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Main findings 
This is the first quantitative demonstration of the benefit of IGRT in partial breast radiotherapy. The 
primary outcome measure was population systematic error.  This was reduced by up to 2 mm with 
IGRT compared to standard imaging hence IGRT was superior.  There was no dependence of 
accuracy on the type of imaging equipment used but the equipment influenced the time taken for 
image assessment. The difference in time between standard imaging and IGRT were small however, 
ranging from 12s to 67s, with 3D methods taking longer than 2D overall, but with better image 
quality justifying the extra time. 
 
The magnitude of population systematic error is important and relevant because it is the main 
contributer to the planning target volume margin and hence to the amount of tissue irradiated to a 
high dose. Our work shows that 5 mm margins are sufficient where IGRT is used, 8 mm margins are 
required for standard bony anatomy based imaging, and 10 mm or greater, if only laser external set 
up is used, or if the results of imaging are not acted upon, i.e. no verification correction protocol is 
employed. The effect of reducing the margin size from 8 mm to 5 mm is to decrease the high dose 
volume by 33cm
3  
(range 11 to 193 cm
3
)
 
[11]. The radiobiological implications of this reduction are 
still uncertain, as discussed by Mukesh et al [12,13].  On-going randomised trials of radiobiological 
effects in breast radiotherapy will produce further essential information on the dose volume effect. 
Work such as IMPORT IGRT will inform the quantitative understanding of this by quantifying the 
impact of margin sizes on irradiated volumes. 
 
Advantages of this approach 
When technological advantages in radiotherapy occur it is important to implement them in a 
controlled, but timely, way for patient benefit. Developments primarily involve generating dose 
distributions which have improved mapping to tumours and spare organs at risk more than the 
standard treatments they replace, and provide greater accuracy in treatment delivery. These give 
the potential to escalate dose to improve cure rates and to reduce adverse effects. 
In some cases, the means to evaluate the benefit of a technological development in a quantitative, 
rigorous ŵaŶŶer is Ŷot Đlear. It is Ŷot ethiĐal to use a ͚ŶoŶ iŶterǀeŶtioŶ͛, or ͚staŶdard iŶterǀeŶtioŶ͛  
ǀersus ͚iŶterǀeŶtioŶ͛ ŵodel ǁhere this Đoŵproŵises patieŶt treatment. IGRT is a good example of 
this. Whilst it is obvious that the use of kV imaging or volumetric imaging at the time of treatment 
gives greater tissue definition, and more information with which to match imaging datasets, the size 
of the benefit is still a pertinent question in determining if the extra complexity, expense and time 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
are justified. Iis difficult to quantify this improvement compared to none/standard imaging without 
two cohorts of patients; one cohort will then not receive the highest quality imaging available : this 
is inconsistent with the principle of equipoise. 
IMPORT-IGRT has allowed the quantitative assessment of IGRT with no reduction in the quality of 
imaging and no additional interventions for the patients. It has achieved this by embedding within 
the IMPORT HIGH trial, maximising the use of the trial data, and being efficient and cost-effective in 
terms of effort. As the protocol requires the highest quality imaging data to ensure the complex 
dose distributions are delivered correctly, it was possible to use the information to deduce the effect 
of a simpler imaging approach. 
Conclusion 
Using this approach the benefit of IGRT has been quantified for the first time in breast radiotherapy. 
The IMPORT-IGRT method demonstrates a successful, efficient method of assessing a development 
in radiotherapy in an ethical, rigorous way by embedding within an existing trial and using complex 
information to determine simpler. We recommend it as an approach which can be adopted for other 
treatment sites and other technology. 
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